Paratek Pharmaceuticals/ US6993743029 /
2023-09-20 10:00:00 PM | Chg. - | Volume | Bid1:50:00 AM | Ask1:50:00 AM | High | Low |
---|---|---|---|---|---|---|
2.2300USD | - | 4.76 mill. Turnover: 9.9 mill. |
2.1800Bid Size: - | 2.2500Ask Size: - | 2.2400 | 2.1900 |
GlobeNewswire
04-18
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated P...
GlobeNewswire
03-05
Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of...
GlobeNewswire
01-16
Paratek Pharmaceuticals Announces Promotion of Jonathan Light to General Counsel, Corporate Secretar...
GlobeNewswire
2023-12-13
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug L...
GlobeNewswire
2023-09-21
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
GlobeNewswire
2023-09-18
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and No...
GlobeNewswire
2023-09-12
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockh...
GlobeNewswire
2023-09-07
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR...
GlobeNewswire
2023-08-27
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CEQP, CELL, DINO, PRTK
GlobeNewswire
2023-08-25
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
2022-03-08
Paratek Pharmaceuticals Announces the Publication of Data from an Investigator-Initiated Study of NU...
GlobeNewswire
2022-03-02
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, ...
GlobeNewswire
2021-12-16
China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment o...
GlobeNewswire
2021-12-16
China NMPA Approves NUZYRA® as a Category 1 Innovative Drug for the Treatment of Patients with Commu...
GlobeNewswire
2021-11-10
Paratek Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
GlobeNewswire
2021-11-08
Paratek Pharmaceuticals Announces Total Revenue of $24.4 Million in the Third Quarter 2021